Literature DB >> 15645392

Cardiac positron emission tomography imaging.

Josef Machac1.   

Abstract

Cardiac positron emission tomography (PET) imaging has advanced from primarily a research tool to a practical, high-performance clinical imaging modality. The widespread availability of state-of-the-art PET gamma cameras, the commercial availability of perfusion and viability PET imaging tracers, reimbursement for PET perfusion and viability procedures by government and private health insurance plans, and the availability of computer software for image display of perfusion, wall motion, and viability images have all been a key to cardiac PET imaging becoming a routine clinical tool. Although myocardial perfusion PET imaging is an option for all patients requiring stress perfusion imaging, there are identifiable patient groups difficult to image with conventional single-photon emission computed tomography imaging that are particularly likely to benefit from PET imaging, such as obese patients, women, patients with previous nondiagnostic tests, and patients with poor left ventricular function attributable to coronary artery disease considered for revascularization. Myocardial PET perfusion imaging with rubidium-82 is noteworthy for high efficiency, rapid throughput, and in a high-volume setting, low operational costs. PET metabolic viability imaging continues to be a noninvasive standard for diagnosis of viability imaging. Cardiac PET imaging has been shown to be cost-effective. The potential of routine quantification of resting and stress blood flow and coronary flow reserve in response to pharmacologic and cold-pressor stress offers tantalizing possibilities of enhancing the power of PET myocardial perfusion imaging. This can be achieved by providing assurance of stress quality control, in enhancing diagnosis and risk stratification in patients with coronary artery disease, and expanding diagnostic imaging into the realm of detection of early coronary artery disease and endothelial dysfunction subject to risk factor modification. Combined PET and x-ray computed tomography imaging (PET-CT) results in enhanced patient throughput and efficiency. The combination of multislice computed tomography scanners with PET opens possibilities of adding coronary calcium scoring and noninvasive coronary angiography to myocardial perfusion imaging and quantification. Evaluation of the clinical role of these creative new possibilities warrants investigation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15645392     DOI: 10.1053/j.semnuclmed.2004.09.002

Source DB:  PubMed          Journal:  Semin Nucl Med        ISSN: 0001-2998            Impact factor:   4.446


  45 in total

1.  ⁸²Rb PET myocardial perfusion imaging is superior to ⁹⁹mTc-labelled agent SPECT in patients with known or suspected coronary artery disease.

Authors:  Albert Flotats; Paco E Bravo; Kenji Fukushima; Muhammad A Chaudhry; Jennifer Merrill; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-31       Impact factor: 9.236

2.  Is it possible for myocardial perfusion imaging to avoid missing any patients with high-risk coronary disease?

Authors:  Mark I Travin
Journal:  J Nucl Cardiol       Date:  2007-07       Impact factor: 5.952

3.  Multicentre assessment and monitored use of [(18)F]FDG-PET in oncology: the Spanish experience.

Authors:  Manuel Rodríguez-Garrido; Cristina Asensio-del-Barrio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-03       Impact factor: 9.236

4.  Activity-based costing evaluation of [18F]-fludeoxyglucose production.

Authors:  Bruno Krug; Annie Van Zanten; Anne-Sophie Pirson; Ralph Crott; Thierry Vander Borght
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-21       Impact factor: 9.236

5.  Comparison of attenuation, dual-energy-window, and model-based scatter correction of low-count SPECT to 82Rb PET/CT quantified myocardial perfusion scores.

Authors:  R Glenn Wells; Karen Soueidan; Rachel Timmins; Terrence D Ruddy
Journal:  J Nucl Cardiol       Date:  2013-06-05       Impact factor: 5.952

6.  Biological characterization of F-18-labeled rhodamine B, a potential positron emission tomography perfusion tracer.

Authors:  Mark D Bartholomä; Huamei He; Christina A Pacak; Patricia Dunning; Frederic H Fahey; Francis X McGowan; Douglas B Cowan; S Ted Treves; Alan B Packard
Journal:  Nucl Med Biol       Date:  2013-09-04       Impact factor: 2.408

7.  Cardiac 82Rubidium PET/CT: initial European experience.

Authors:  Ashley M Groves; Marie-Elsya Speechly-Dick; John C Dickson; Irfan Kayani; Raymondo Endozo; Patty Blanchard; Manu Shastry; Elizabeth Prvulovich; Wendy A Waddington; Simona Ben-Haim; Jamshed B Bomanji; Jean R McEwan; Peter J Ell
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-31       Impact factor: 9.236

8.  Independent and incremental prognostic value of left ventricular ejection fraction determined by stress gated rubidium 82 PET imaging in patients with known or suspected coronary artery disease.

Authors:  Kirkeith Lertsburapa; Alan W Ahlberg; Timothy M Bateman; Deborah Katten; Lyndy Volker; S James Cullom; Gary V Heller
Journal:  J Nucl Cardiol       Date:  2008-09-12       Impact factor: 5.952

9.  Rubidium-82 PET-CT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis.

Authors:  Riikka Lautamäki; Richard T George; Kakuya Kitagawa; Takahiro Higuchi; Jennifer Merrill; Corina Voicu; Anthony DiPaula; Stephan G Nekolla; João A C Lima; Albert C Lardo; Frank M Bengel
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-05       Impact factor: 9.236

10.  A novel gallium bisaminothiolate complex as a myocardial perfusion imaging agent.

Authors:  Karl Plössl; Rajesh Chandra; Wenchao Qu; Brian P Lieberman; Mei-Ping Kung; Rong Zhou; Bin Huang; Hank F Kung
Journal:  Nucl Med Biol       Date:  2007-11-19       Impact factor: 2.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.